Todd has more than 20 years of experience in counseling and strategic planning in complex intellectual property issues for startups and small and large multi-billion-dollar global companies in the pharmaceutical, medical device, and biotechnology industries. Todd regularly serves as a trusted adviser and de facto chief IP counsel for several startup and smaller clients, including those pursuing small molecule therapeutics, immunological therapies, cell and gene therapies, molecular diagnostics, pharmaceutical manufacturing, and AI-based RNA products.
Todd has significant experience in virtually all facets of life science technology and represented Nobel laureates involving the seminal work in gene silencing. His strong scientific background enables him to proactively counsel clients on a broad range of life science intellectual property issues including developing patent portfolios surrounding key platform technologies, patent portfolio lifecycle management, complex dispute strategies, freedom-to-operate, and invalidity analyses. He has conducted and led numerous diligence analyses for transactions involving a wide variety of pharmaceutical, immunologic, gene, and cell-based therapies.
In addition, Todd has substantial experience in district court litigation and USPTO inter partes disputes. He has been lead trial counsel in Interference proceedings, Section 145 appeals and State Trade Secret Misappropriation actions.
Todd earned his bachelor’s degree from Oglethorpe University, his Ph.D. in pharmacology and toxicology from the University of Georgia, and his law degree from George Washington School of Law.